RSS feed

Publications by Paal F. Brunsvig

37 publications found

Original articles

Ellingsen EB, Aamdal E, Guren T, Lilleby W, Brunsvig PF, Mangsbo SM, Aamdal S, Hovig E, Mensali N, Gaudernack G, Inderberg EM (2022)
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
J Immunother Cancer, 10 (5)
DOI 10.1136/jitc-2021-004345, PubMed 35613827

Aamdal E, Inderberg EM, Ellingsen EB, Rasch W, Brunsvig PF, Aamdal S, Heintz KM, Vodák D, Nakken S, Hovig E, Nyakas M, Guren TK, Gaudernack G (2021)
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
Front Immunol, 12, 663865
DOI 10.3389/fimmu.2021.663865, PubMed 34046035

Spicer J, Marabelle A, Baurain JF, Jebsen NL, Jøssang DE, Awada A, Kristeleit R, Loirat D, Lazaridis G, Jungels C, Brunsvig P, Nicolaisen B, Saunders A, Patel H, Galon J, Hermitte F, Camilio KA, Mauseth B, Sundvold V, Sveinbjørnsson B, Rekdal Ø (2021)
Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors
Clin Cancer Res, 27 (10), 2755-2763
DOI 10.1158/1078-0432.CCR-20-3435, PubMed 33542073

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Valan CD, Slagsvold JE, Halvorsen TO, Herje M, Bremnes RM, Brunsvig PF, Brustugun OT, Fløtten Ø, Levin N, Sundstrøm SH, Grønberg BH (2018)
Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement
Anticancer Res, 38 (2), 871-876
DOI 10.21873/anticanres.12296, PubMed 29374714

Felip E, Barlesi F, Besse B, Chu Q, Gandhi L, Kim SW, Carcereny E, Sequist LV, Brunsvig P, Chouaid C, Smit EF, Groen HJM, Kim DW, Park K, Avsar E, Szpakowski S, Akimov M, Garon EB (2017)
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer
J Thorac Oncol, 13 (4), 576-584
DOI 10.1016/j.jtho.2017.11.131, PubMed 29247830

Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM (2017)
Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer
Cancer Immunol Immunother, 66 (7), 891-901
DOI 10.1007/s00262-017-1994-y, PubMed 28391357

Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Wälchli S, Pule M (2016)
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
Oncoimmunology, 5 (12), e1249090
DOI 10.1080/2162402X.2016.1249090, PubMed 28123886

Halvorsen TO, Sundstrøm S, Fløtten Ø, Brustugun OT, Brunsvig P, Aasebø U, Bremnes RM, Kaasa S, Grønberg BH (2016)
Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer
Acta Oncol, 55 (11), 1349-1354
DOI 10.1080/0284186X.2016.1201216, PubMed 27549509

Ardizzoni A, Tiseo M, Boni L, Di Maio M, Buffoni L, Belvedere O, Grossi F, D'Alessandro V, de Marinis F, Barbera S, Caroti C, Favaretto A, Cortinovis D, Morrica B, Tixi L, Ceschia T, Parisi S, Ricardi U, Grimaldi A, Loreggian L, Navarria P, Huber RM, Belani C, Brunsvig PF, Scagliotti GV et al. (2016)
Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC
Lung Cancer, 100, 30-37
DOI 10.1016/j.lungcan.2016.07.026, PubMed 27597278

Andersson Y, Engebraaten O, Juell S, Aamdal S, Brunsvig P, Fodstad Ø, Dueland S (2015)
Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
Br J Cancer, 113 (11), 1548-55
DOI 10.1038/bjc.2015.380, PubMed 26554649

Hansen GL, Gaudernack G, Brunsvig PF, Cvancarova M, Kyte JA (2015)
Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination
Cancer Immunol Immunother, 64 (12), 1609-21
DOI 10.1007/s00262-015-1766-5, PubMed 26498005

Grønberg BH, Halvorsen TO, Fløtten Ø, Brustugun OT, Brunsvig PF, Aasebø U, Bremnes RM, Tollåli T, Hornslien K, Aksnessæther BY, Liaaen ED, Sundstrøm S, Norwegian Lung Cancer Study Group (2015)
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer
Acta Oncol, 55 (5), 591-7
DOI 10.3109/0284186X.2015.1092584, PubMed 26494411

Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S (2011)
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial
Clin Cancer Res, 17 (21), 6847-57
DOI 10.1158/1078-0432.CCR-11-1385, PubMed 21918169

Strand TE, Brunsvig PF, Johannessen DC, Sundstrøm S, Wang M, Hornslien K, Bremnes RM, Stensvold A, Garpestad O, Norstein J (2010)
Potentially curative radiotherapy for non-small-cell lung cancer in Norway: a population-based study of survival
Int J Radiat Oncol Biol Phys, 80 (1), 133-41
DOI 10.1016/j.ijrobp.2010.01.050, PubMed 20452137

Edvardsen H, Brunsvig PF, Solvang H, Tsalenko A, Andersen A, Syvanen AC, Yakhini Z, Børresen-Dale AL, Olsen H, Aamdal S, Kristensen VN (2010)
SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance
Pharmacogenomics J, 10 (6), 513-23
DOI 10.1038/tpj.2010.6, PubMed 20157331

Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S (2009)
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer
J Clin Oncol, 27 (19), 3217-24
DOI 10.1200/JCO.2008.20.9114, PubMed 19433683

Gunnes N, Seierstad TG, Aamdal S, Brunsvig PF, Jacobsen AB, Sundstrøm S, Aalen OO (2009)
Assessing quality of life in a randomized clinical trial: correcting for missing data
BMC Med Res Methodol, 9, 28
DOI 10.1186/1471-2288-9-28, PubMed 19405936

Grønberg BH, Bremnes RM, Aasebø U, Brunsvig P, Fløtten O, Amundsen T, von Plessen C, Wang M, Sundstrøm S, Norwegian Lung Cancer Study Group (2008)
A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer
Lung Cancer, 63 (1), 88-93
DOI 10.1016/j.lungcan.2008.04.003, PubMed 18538889

Helbekkmo N, Aasebø U, Sundstrøm SH, von Plessen C, Brunsvig PF, Bremnes RM, Norwegian Lung Cancer Study Group (2008)
Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy
Lung Cancer, 62 (2), 253-60
DOI 10.1016/j.lungcan.2008.03.003, PubMed 18417246

Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, Peters S, Brunsvig P, Montes A, Lange A, Yilmaz U, Rosti G, Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation (2008)
A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial
J Natl Cancer Inst, 100 (8), 533-41
DOI 10.1093/jnci/djn088, PubMed 18398095

Brunsvig PF, Flatmark K, Aamdal S, Høifødt H, Le H, Jakobsen E, Sandstad B, Fodstad O (2008)
Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients
Lung Cancer, 61 (2), 170-6
DOI 10.1016/j.lungcan.2007.12.018, PubMed 18261824

Brunsvig PF, Andersen A, Aamdal S, Kristensen V, Olsen H (2007)
Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy
BMC Cancer, 7, 197
DOI 10.1186/1471-2407-7-197, PubMed 17956601

Helbekkmo N, Sundstrøm SH, Aasebø U, Brunsvig PF, von Plessen C, Hjelde HH, Garpestad OK, Bailey A, Bremnes RM, Norwegian Lung Cancer Study Group (2007)
Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
Br J Cancer, 97 (3), 283-9
DOI 10.1038/sj.bjc.6603869, PubMed 17595658

Sundstrøm S, Bremnes RM, Brunsvig P, Aasebø U, Kaasa S, Norwegian Lung Cancer Study Group (2006)
Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy?
J Thorac Oncol, 1 (8), 816-24
PubMed 17409965

Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Møller M, Eriksen JA, Gaudernack G (2006)
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer
Cancer Immunol Immunother, 55 (12), 1553-64
DOI 10.1007/s00262-006-0145-7, PubMed 16491401

Andersen A, Warren DJ, Brunsvig PF, Aamdal S, Kristensen GB, Olsen H (2006)
High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection
BMC Clin Pharmacol, 6, 2
DOI 10.1186/1472-6904-6-2, PubMed 16412237

Brunsvig PF, Hatlevoll R, Berg R, Lauvvang G, Owre K, Wang M, Aamdal S (2005)
Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: a phase I/II study with 5 years' follow-up
Lung Cancer, 50 (1), 97-105
DOI 10.1016/j.lungcan.2005.05.010, PubMed 16005105

Sundstrøm S, Bremnes R, Brunsvig P, Aasebø U, Olbjørn K, Fayers PM, Kaasa S, Norwegian Lung Cancer Study Group (2005)
Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study
Radiother Oncol, 75 (2), 141-8
DOI 10.1016/j.radonc.2005.03.028, PubMed 16094739

Sundstrøm S, Bremnes R, Aasebø U, Aamdal S, Hatlevoll R, Brunsvig P, Johannessen DC, Klepp O, Fayers PM, Kaasa S (2004)
Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial
J Clin Oncol, 22 (5), 801-10
DOI 10.1200/JCO.2004.06.123, PubMed 14990635

Borge LM, Brunsvig PF, Ritland S, Stene-Larsen G, Hannisdal E (1997)
[The project Better Cancer Care in Buskerud]
Tidsskr Nor Laegeforen, 117 (15), 2170-3
PubMed 9235704

Brunsvig PF, Os I, Frederichsen P (1990)
[Hyponatremia. A retrospective study of occurrence, etiology and mortality]
Tidsskr Nor Laegeforen, 110 (18), 2367-9
PubMed 2218994

Brunsvig PF, Reikvam A, Nordgård S (1987)
[Protracted digitalis poisoning]
Tidsskr Nor Laegeforen, 107 (9), 843-4
PubMed 3590123

Other articles

Brunsvig PF, Guren TK, Nyakas M, Steinfeldt-Reisse CH, Rasch W, Kyte JA, Juul HV, Aamdal S, Gaudernack G, Inderberg EM (2020)
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
Front Immunol, 11, 572172
DOI 10.3389/fimmu.2020.572172, PubMed 33324397

Books

Brunsvig P, Østbø LL (1970)
Moms: merverdi- og investeringsavgift i praksis
Tanum, Oslo (3. oppl.), 2 b.
BIBSYS 070324506

Brunsvig P, Østbø LL (1969)
Moms: merverdi- og investeringsavgift i praksis
Tanum, Oslo, 2 b.
BIBSYS 887018335

Theses

Brunsvig PF (2008)
New diagnostic and therapeutic approaches in non-small cell lung cancer
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 675, 1 b. (flere pag.)
BIBSYS 082538034, ISBN 978-82-8072-475-5